- Home
- BSET vs MOLN Comparison
BSET vs MOLN Comparison
Compare BSET & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSET | MOLN |
|---|---|---|
| Founded | 1902 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.9M | 170.5M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BSET | MOLN |
|---|---|---|
| Price | $21.22 | $3.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.36 |
| AVG Volume (30 Days) | ★ 21.1K | 1.6K |
| Earning Date | 09-30-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.82% | N/A |
| EPS Growth | ★ 163.06 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $456,855,000.00 | N/A |
| Revenue This Year | $0.85 | N/A |
| Revenue Next Year | $3.42 | $450.00 |
| P/E Ratio | $34.33 | ★ N/A |
| Revenue Growth | ★ 0.96 | N/A |
| 52 Week Low | $13.17 | $3.53 |
| 52 Week High | $22.26 | $5.36 |
Technical Indicators
Market Signals| Indicator | BSET | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 71.87 | 41.35 |
| Support Level | $13.90 | N/A |
| Resistance Level | $22.26 | $4.35 |
| Average True Range (ATR) | 0.68 | 0.16 |
| MACD | 0.40 | -0.05 |
| Stochastic Oscillator | 96.51 | 3.09 |
Price Performance
Historical ComparisonAbout BSET Bassett Furniture Industries Incorporated
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.